Shire Confirms Rejection of AbbVie Proposal - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Shire Confirms Rejection of AbbVie Proposal


In a June 20 statement, Shire confirms that the board had rejected a May 30, 2014 “unsolicited and highly conditional proposal” from AbbVie regarding a possible cash and share offer for Shire. Reuters estimated the value of the offer at $46 billion (27 billion-pounds).

Shire reports that the offer undermined the value of the company and its prospects, and the board had concerns with execution risks associated with the proposed structure, as AbbVie would redomicile in the UK for tax purposes.

The May 30 proposal followed two earlier proposals, which were also rejected, Shire reports. At AbbVie's request, Shire met with AbbVie to discuss key aspects of the Proposal. Following the meeting, Shire's board decided unanimously to reject the proposal on the basis that it fundamentally undervalued the company and its prospects.

Sources:
Shire
Reuters

 

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here